Paper Details

  1. Home
  2. Paper Details

Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.

Author: AmmannRoland A, AndersonRichard A, AttarbaschiAndische, BalwierzWalentyna, BarteltJörg M, BeishuizenAuke, BoudjemaaSabah, CepelovaMichaela, ClaviezAlexander, DawStephen, DieckmannKarin, Fernández-TeijeiroAna, FossåAlexander, GattenlöhnerStefan, GeorgiThomas, HasencleverDirk, HjalgrimLisa L, HraskovaAndrea, KarlénJonas, KlugeRegine, KurchLars, KörholzDieter, Landman-ParkerJudith, LeblancThiery, MannGeorg, Mauz-KörholzChristine, MontraversFrancoise, PearsJean, PelzTanja, RajićVladan, RamsayAlan D, StoevesandtDietrich, UyttebroeckAnne, VordermarkDirk, WallaceWilliam Hamish

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the potential for omitting radiotherapy in patients with classical Hodgkin lymphoma who achieve a good response to chemotherapy, as well as the impact of modified consolidation chemotherapy on gonadotoxicity.
Paper Details　
Original Abstract of the Article :
Children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma achieve an event-free survival at 5 years of about 90% after treatment with vincristine, etoposide, prednisone, and doxorubicin (OEPA) followed by cyclophosphamide, vincristine, prednisone, and procarbazin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716340/

データ提供：米国国立医学図書館（NLM）

Response-Adapted Omission of Radiotherapy and Comparison of Consolidation Chemotherapy in Children and Adolescents with Intermediate-Stage and Advanced-Stage Classical Hodgkin Lymphoma (EuroNet-PHL-C1): A Titration Study with an Open-Label, Embedded, Multinational, Non-inferiority, Randomized Controlled Trial

This comprehensive [clinical trial] focuses on the treatment of [Hodgkin lymphoma] in children and adolescents. The study aimed to investigate whether [radiotherapy] could be omitted in patients who showed a favorable response to initial treatment. The authors also explored the effectiveness of a modified [consolidation chemotherapy] regimen in reducing [gonadotoxicity]. This groundbreaking research has the potential to significantly impact the treatment of [Hodgkin lymphoma], offering a less invasive and more tailored approach for patients.

Reducing Treatment Burden and Gonadotoxicity

The [EuroNet-PHL-C1 trial] demonstrates the potential to reduce the burden of [radiotherapy] in patients with [Hodgkin lymphoma] who respond well to initial treatment. The findings suggest that [modified consolidation chemotherapy] may effectively reduce [gonadotoxicity] while maintaining favorable treatment outcomes. This study's results highlight the importance of [personalized medicine] in cancer treatment, allowing clinicians to tailor treatment approaches based on individual patient characteristics.

Tailoring Treatment for a Better Future

This research, like a map guiding us through the complex landscape of [cancer treatment], offers a path towards more personalized and less invasive approaches. The study's findings suggest that [radiotherapy] may not be necessary for all patients with [Hodgkin lymphoma] who show favorable response to initial treatment. This is a significant advancement in the field, offering patients a better quality of life and potentially reducing long-term side effects. The study also underscores the importance of considering [gonadotoxicity] when designing treatment regimens for children and adolescents.

Dr.Camel's Conclusion

This study, like a camel caravan navigating the challenging terrain of [cancer treatment], has unearthed a promising path towards less invasive and more personalized approaches. The findings offer hope for children and adolescents with [Hodgkin lymphoma] by providing a more tailored treatment strategy. As we continue our journey through the desert of medical innovation, we strive to find the most effective and least burdensome treatments for our patients.

Date :
  1. Date Completed 2022-02-24
  2. Date Revised 2022-12-29
Further Info :

Pubmed ID

34895479

DOI: Digital Object Identifier

PMC8716340

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.